Sobi acquires NovImmune’s Immunology Business in CHF 515 Mio. Deal
13 June 2019 – Swedish Orphan Biovitrum AB (Sobi) (STO:SOBI) and NovImmune SA announced the transaction relating to the sale of the emapalumab business spun-off from NovImmune. The total consideration for the acquisition is CHF 515 mio. The transaction shall be completed during Q3 2019.
NovImmune SA is a privately held Swiss biopharmaceutical company with more than 140 employees operating from Geneva and Basel, Switzerland. The lead drug emapalumab is the first and only medicine approved in the US for primary HLH, a rare syndrome of hyperinflammation that usually occurs within the first year of life and can rapidly become fatal unless diagnosed and treated. Sobi is an international biopharmaceutical company listed on Nasdaq Stockholm.
Walder Wyss has acted as legal counsel to NovImmune’s management team as sellers. The Walder Wyss team is being led by Alex Nikitine (Partner, Corporate/M&A, Capital Markets) and further included Dimitrios Berger (Associate, Corporate/M&A), Thomas Meister (Partner, Tax), Michael Isler (Partner, IP/IT), Janine Corti (Counsel, Tax), Christian Hagen (Associate, Corporate/M&A) and Daniel Donauer (Associate, Corporate/M&A).